Royalty Pharma plc
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M | $975.0M | $2.35B | $1.38B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $3.9M | $0 | $0 | — | — | — | — | — |
| Amortization | — | $0 | $0 | $5.7M | $23.0M | $23.1M | $23.9M | $33.3M |
| Stock-Based Compensation | $289.9M | $2.3M | $2.4M | $2.2M | $2.4M | $5.4M | $0 | $0 |
| Net Cash from Operating Activities | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B | $1.67B | $1.62B |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | $74.4M | $0 | $0 | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.61B | $-2.68B | $-2.07B | $-1.03B | $-1.87B | $-2.76B | $-2.15B | $303.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $1.23B | $229.7M | $304.8M | $0 | $0 | $0 | $4.3M | $0 |
| Net Cash from Financing Activities | $-1.19B | $361.1M | $-2.15B | $-944.9M | $385.1M | $1.49B | $-1.19B | $-1.38B |
| Net Change in Cash | $-310.3M | $452.0M | $-1.23B | $169.7M | $532.4M | $762.5M | $-1.68B | $542.6M |
| Free Cash Flow | — | — | — | — | — | — | — | — |